Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Conditions Studied
Interventions
- DRUG Elranatamab
- DRUG Iberdomide
Study Locations (20)
Massachusetts
- Brigham and Women's Hospital — Boston
- Dana-Farber Cancer Institute — Boston
- Dana-Farber Cancer Institute - Chestnut Hill — Newton
- University of Massachusetts Chan Medical School — Worcester
- University of Massachusetts Chan Medical School — Worcester
Georgia
- Emory University Hospital Midtown — Atlanta
- Emory University Hospital — Atlanta
- Winship Cancer Institute of Emory University — Atlanta
- Winship Cancer Institute — Atlanta
Indiana
- Indiana CTSI Clinical Research Center (ICRC) — Indianapolis
- Indiana University Health University Hospital — Indianapolis
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) — Indianapolis
Nebraska
- Methodist Hospital — Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer - Methodist — Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists — Omaha
New Jersey
- MSK Basking Ridge — Basking Ridge
- MSK Monmouth — Middletown
- MSK Bergen — Montvale
Maryland
- University of Maryland — Baltimore
New Hampshire
- Dartmouth-Hitchcock Medical Center — Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2028-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06215118
The ClinicalTrials.gov registry entry for NCT06215118 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions — of which Elranatamab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06215118 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Massachusetts, Georgia, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06215118 about?
NCT06215118 is a clinical study titled "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)". The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination th...
What is the current status of trial NCT06215118?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2024-02-20. Estimated completion is 2028-03-09.
What conditions does trial NCT06215118 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06215118?
The interventions under investigation include: Elranatamab (DRUG), Iberdomide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06215118?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06215118 being conducted?
This trial has 20 study locations across Georgia, Indiana, Maryland, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.